| Title |
Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet
|
|---|---|
| Published in |
Current Atherosclerosis Reports, November 2016
|
| DOI | 10.1007/s11883-016-0633-y |
| Pubmed ID | |
| Authors |
James H. Flory, Jenny K. Ukena, James S. Floyd |
| Abstract |
The purpose is to review evidence on cardiovascular risks and benefits of new treatments for type 2 diabetes mellitus. In response to guidance issued by the Food and Drug Administration, thousands of patients have been enrolled in large randomized trials evaluating the cardiovascular effects of the three newest diabetes drug classes: glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Two studies of GLP-1 receptor agonists-one of liraglutide and one of semaglutide-have shown cardiovascular benefit relative to placebo, and one study of the SGLT-2 inhibitor empagliflozin has shown benefit. The other published cardiovascular outcome studies of the newest drug classes have generally supported safety, apart from an as-yet unresolved safety concern about increased rates of heart failure with DPP-4 inhibitors. Recent research suggests the thiazolidinedione pioglitazone may have beneficial effects on some cardiovascular outcomes as well, but these are counterbalanced by a known increase of the risk of heart failure with this drug. In general, more prospective randomized trial data is now available regarding the cardiovascular effects of the newer diabetes drugs than on the older drug classes. New evidence suggests that the newest diabetes drugs are safe from a cardiovascular perspective. Evidence on benefit from at least some members of the GLP-1 receptor agonist and SGLT-2 inhibitor classes is encouraging but not yet decisive. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 117 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 21% |
| Student > Master | 20 | 17% |
| Student > Bachelor | 12 | 10% |
| Other | 11 | 9% |
| Student > Ph. D. Student | 5 | 4% |
| Other | 10 | 9% |
| Unknown | 35 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 8% |
| Nursing and Health Professions | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Chemistry | 2 | 2% |
| Other | 1 | <1% |
| Unknown | 40 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 January 2017.
All research outputs
#18,518,987
of 22,940,083 outputs
Outputs from Current Atherosclerosis Reports
#648
of 767 outputs
Outputs of similar age
#235,754
of 311,813 outputs
Outputs of similar age from Current Atherosclerosis Reports
#14
of 17 outputs
Altmetric has tracked 22,940,083 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 767 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,813 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.